IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 126-150 out of 1332.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

Public Release: 14-Apr-2015
American Association for Cancer Research Annual Meeting 2015
PharmaMar to present data on anticancer candidates PM1183 and plitidepsin at the AACR 2015
The new data on PharmaMar's anticancer compounds PM1183 and plitidepsin will be discussed at the AACR 2015 during poster sessions throughout the meeting. The company will present data on new molecular targets, mechanisms of actions of the compounds and combination studies in preclinical models of cancer.

Contact: Carolina Pola
cpola@pharmamar.com
34-608-933-677
Pharmamar

Public Release: 14-Apr-2015
Gynecologic Oncology
New biomarker for uterine cancer discovered
Researchers at Uppsala University have, together with researchers from Turku and Bergen, discovered a new biomarker which makes it possible to identify women with uterine cancer who have a high risk of recurrence. The findings were recently published in the journal Gynecologic Oncology.

Contact: Per-Henrik Edqvist
per-henrik.edqvist@igp.uu.se
46-735-457-760
Uppsala University

Public Release: 14-Apr-2015
Cancer Cell
Rare, deadly lymphoma demystified
This is the first-ever systematic study of the genomes of patients with ALK-negative anaplastic large cell lymphoma, a particularly aggressive form of non-Hodgkin's lymphoma.
National Institutes of Health

Contact: Lucky Tran
lt2549@columbia.edu
212-305-3689
Columbia University Medical Center

Public Release: 14-Apr-2015
Cancer Research
Researchers discover an inactive tumor suppressor gene in lung cancer
Researchers at Genes and Cancer group at Bellvitge Biomedical Research Institute, led by Montse Sanchez-Cespedes, have identified the PARD3 gene as a tumor suppressor that is inactivated in lung cancer squamous type. The results of the study have been published in Cancer Research.

Contact: Arantxa Mena
amena@idibell.cat
34-932-607-282
IDIBELL-Bellvitge Biomedical Research Institute

Public Release: 14-Apr-2015
mBio
Genetically engineered Salmonella promising as anti-cancer therapy
A new study has demonstrated that genetically modified Salmonella can be used to kill cancer cells. The study is published in this week's issue of mBio, an American Society for Microbiology online-only, open-access journal.

Contact: Aleea Khan
akhan@asmusa.org
American Society for Microbiology

Public Release: 14-Apr-2015
Journal of Cell Biology
High fidelity: SLU researcher finds keys to genome integrity
Lesions in DNA can occur as often as 100,000 times per cell per day. Saint Louis University researchers share a discovery that explains how cells use a process called replication fork reversal in order to deal with these roadblocks and transmit accurate genetic data.
National Institutes of Health, Saint Louis University Cancer Center

Contact: Carrie Bebermeyer
bebermcl@slu.edu
314-977-8015
Saint Louis University

Public Release: 14-Apr-2015
American Journal of Gastroenterology
New treatment for common digestive condition Barrett's esophagus
New research from the University of Warwick and University Hospitals Coventry and Warwickshire NHS Trust could transform treatments and diagnosis for a common digestive condition which affects thousands of patients.

Contact: Kelly Parkes-Harrison
k.e.parkes@warwick.ac.uk
0247-615-0868
University of Warwick

Public Release: 14-Apr-2015
Cancer Cell
Recruiting the entire immune system to attack cancer
MIT studies finds that stimulating both major branches of the immune system halts tumor growth more effectively.
NIH/National Cancer Institute, NIH/National Institute for General Medical Sciences, National Science Foundation

Contact: Sarah McDonnell
s_mcd@mit.edu
617-253-8923
Massachusetts Institute of Technology

Public Release: 13-Apr-2015
Nature Medicine
Researchers identify drug target for ATRA, the first precision cancer therapy
Cancerous tumors have the unique ability to activate alternative pathways to evade targeted therapy. They also contain cancer stem cells that can make them more aggressive and drug-resistant. Now researchers in the Cancer Research Institute at Beth Israel Deaconess Medical Center have identified a drug target that can address both of these challenges in two cancer types.

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center

Public Release: 13-Apr-2015
Proceedings of the National Academy of Sciences
Molecular signature for outcomes of triple negative breast cancer
Compared to other types of breast cancer, triple negative breast cancers are often more aggressive and have fewer treatment options. In a new study published in the journal Proceedings of the National Academy of Sciences, researchers at Huntsman Cancer Institute and the University of Utah have identified a molecular mechanism that triple negative breast cancer cells use to survive and grow.
National Institutes of Health, Huntsman Cancer Foundation, Cancer Center Support Grant, China Scholarship Council Grant

Contact: Linda Aagard
linda.aagard@hci.utah.edu
801-587-7639
University of Utah Health Sciences

Public Release: 13-Apr-2015
Proceedings of the National Academy of Sciences
Pitt cancer virology team reveals new pathway that controls how cells make proteins
A serendipitous combination of technology and scientific discovery, coupled with a hunch, allowed University of Pittsburgh Cancer Institute researchers to reveal a previously invisible biological process that may be implicated in the rapid growth of some cancers.
National Institutes of Health, NIH/National Cancer Institute

Contact: Allison Hydzik
Hydzikam@upmc.edu
University of Pittsburgh Schools of the Health Sciences

Public Release: 13-Apr-2015
PLOS ONE
Brazilian study suggests adjustments on the treatment of cancer patients with pneumonia
Pneumonia is the most frequent type of infection in cancer patients and it is associated with high mortality rates. Brazilian researchers analyzed the factors associated with severe pneumonia in hospitalized cancer patients and suggest that personalized treatment protocols can reduce mortality in this population. Their work indicates that the standard broad-spectrum antibiotic treatment used by physicians worldwide may not be the better choice for this group.

Contact: Jorge Salluh
jorgesalluh@gmail.com
D'Or Institute for Research and Education

Public Release: 13-Apr-2015
Nature Cell Biology
Heart cells regenerated in mice
Weizmann Institute research gets mouse heart cells to take a step backwards so they can be renewed.

Contact: Yael Edelman
yael.edelman@weizmann.ac.il
Weizmann Institute of Science

Public Release: 13-Apr-2015
Cancer
HPV vaccination of adolescent boys may be cost-effective for preventing oropharyngeal cancer
A new study indicates that vaccinating 12-year-old boys against the humanpapilloma virus may be a cost-effective strategy for preventing oropharyngeal squamous cell cancer, a cancer that starts at the back of the throat and mouth, and involves the tonsils and base of the tongue.

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
Wiley

Public Release: 13-Apr-2015
Proceedings of the National Academy of Sciences
Smartphone-based device could provide rapid, low-cost molecular tumor diagnosis
A device developed by Massachusetts General Hospital investigators may bring rapid, accurate molecular diagnosis of tumors and other diseases to locations lacking the latest medical technology.
National Institutes of Health, US Department of Defense

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 13-Apr-2015
Oncogene
U-M researchers find protein that may signal more aggressive prostate cancers
University of Michigan researchers have discovered a biomarker that may be a potentially important breakthrough in diagnosing and treating prostate cancer.

Contact: Laura Bailey
baileylm@umich.edu
734-647-1848
University of Michigan

Public Release: 13-Apr-2015
Developmental Cell
CNIO experts identify an oncogene regulated by nutrients
In response to nutrient excess, the MCRS1 protein acts as a 'switch' for mTOR, a protein that is altered in cancer, diabetes and disorders associated with aging. The results correlate with increased MCRS1 protein levels in samples taken from patients with colorectal cancer. Blocking this protein may prove to be an effective treatment for cancer or other diseases associated with mTOR alterations.

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 13-Apr-2015
Proceedings of the National Academy of Sciences
Moffitt develops new method to characterize the structure of a protein that promotes tumor growth
offitt Cancer Center researchers have developed a new method to identify a previously unknown structure in a protein called MDMX. MDMX is a crucial regulatory protein that controls p53 -- one of the most commonly mutated genes in cancer.
National Institutes of Health, Florida Department of Health

Contact: Kim Polacek
Kim.Polacek@Moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 13-Apr-2015
Proceedings of the National Academy of Sciences
Gold by special delivery intensifies cancer-killing radiation
Researchers at Brown and the University of Rhode Island have demonstrated what could become a more precise method for targeting cancer cells for radiation. The method would use cancer-seeking peptides to ferry nanoparticles of gold to the site. The gold then helps focus radiation on the cancer cells.
National Institutes of Health

Contact: Kevin Stacey
kevin_stacey@brown.edu
401-863-3766
Brown University

Public Release: 13-Apr-2015
Health Affairs
The cost and quality of cancer care in Health Affairs' April issue
The April issue of Health Affairs contains a cluster of papers focusing on the cost and quality of cancer care. Other subjects covered in the issue: health care payment reform and the diminished number of uninsured young adults. Publication of the cancer studies in the April issue was supported by Precision Health Economics and the Celgene Corporation.

Contact: Sue Ducat
sducat@projecthope.org
301-841-9962
Health Affairs

Public Release: 13-Apr-2015
Cancer Cell
Two Cell Press journals review relationship between immune system and cancer
In a joint special issue on cancer, immunity, and immunotherapy, Cancer Cell and Trends in Immunology explore the history of this work and review how immunology and cancer research currently intersect. Articles explore drugs that eliminate cancer's hold on the immune system, as well as the ways the immune response is affected by anti-cancer therapies and vice versa.

Contact: Joseph Caputo
jcaputo@cell.com
617-335-6270
Cell Press

Public Release: 13-Apr-2015
Digestive and Liver Diseases
Mayo profile identifies patients most at risk of developing pancreatic cancer
When people learn they have a lesion in their pancreas that could become pancreatic cancer, they often request frequent CT scans and biopsies, or surgery. Often the lesion is nothing to worry about. A team of international physicians, led by researchers at Mayo Clinic's campus in Jacksonville, Florida, has developed a profile of the patient most at risk of developing lesions that are most likely to develop into cancer.
Mayo Clinic/Joyce E. Baker Foundation

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-0746
Mayo Clinic

Public Release: 13-Apr-2015
Cancer Cell
Melanoma's 'safe haven' targeted for shut-down
Melanoma cells become drug resistant by using surrounding healthy cells to provide a 'safe haven' from treatment, according to new research published in Cancer Cell on April 13, 2015.
Cancer Research UK

Contact: Paul Thorne
paul.thorne@cancer.org.uk
44-203-469-8352
Cancer Research UK

Public Release: 13-Apr-2015
British Journal of Cancer
Study finds testicular cancer link for muscle-building supplements
A new study associates taking muscle-building supplements with an increased risk of testicular cancer. Men who used such pills and powders were more likely to have developed testicular cancer than those who did not, especially if they started before age 25, took more than one supplement, or used the supplements for three or more years.
National Institutes of Health, National Natural Science Foundation of China, Beijing Natural Science Foundation, Beijing Nova Program

Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University

Public Release: 13-Apr-2015
Cancer Cell
Promising developments in tackling resistance to blood cancer drugs
A drug with the potential to reverse resistance to immunotherapy has been developed by scientists at the University of Southampton. It has shown great promise in pre-clinical models and will be available to patients with certain leukemias and non-Hodgkin lymphomas in clinical trials later this year. Targeted drugs made from engineered immune proteins -- called monoclonal antibodies -- have revolutionized treatment for several types of cancer in recent years.
Leukaemia & Lymphoma Research, Cancer Research UK

Contact: Charles Elder
c.elder@soton.ac.uk
44-023-805-98933
University of Southampton

Showing releases 126-150 out of 1332.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

  Search News Releases

     

Featured Multimedia

 

EurekAlert!